Top Doctor Top Doctor
The Top Doctor award is a peer-nominated award for providers who give exceptional care.

Evan Y. Yu, MD

Clinical Research Director, Genitourinary Medical Oncology
Seattle Cancer Care Alliance
Professor, Medical Oncology
University of Washington School of Medicine
Assistant Fellowship Director
UW Medicine
Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Director, Clinical Research Support
Fred Hutchinson Cancer Research Consortium
Specialty:
Medical Oncology
“Scientific understanding and science-based treatments are important, but there’s so much more to treating cancer.”
— Dr. Yu
How do you combine being a scientist and physician?

I always had a scientific bent and wanted to be a physician. The summer after my first year of med school, I worked with a urologist and met men being treated for prostate cancer. The patients, who were grappling with their diagnosis and considering their options, inspired me to specialize in oncology. I felt deep respect and compassion for those undergoing cancer treatment, but that really deepened once my father developed bladder cancer. Before my father’s illness, I was very much a molecular scientist. But having someone close to me get cancer made me think about the disease more holistically, rather than only as a ball of abnormal cells or a sample in a tissue culture dish. Now, I find myself dedicated to strengthening the links between clinical care and lab research so that the prognosis for patients only gets better and better. Today, I try to meld the clinical care and the biology. I’m passionate about searching for the next wave of cancer treatments — targeted agents with greater cancer specificity and fewer side effects for you.

Yu_Evan_Secondary.jpg
What do you uniquely bring to patients?

I plant myself directly on the line between the laboratory and the clinic and engage both sides to develop a personalized approach to a selection of novel therapies. Your medical care needs to be built on a foundation of science and education, but I also bring an added dimension to my job by understanding biologic mechanisms of drug sensitivity and resistance. It’s really about working with you as a whole person, not just your cancer. I also recognize the importance of your relationship with your circle of loved ones. Oncology gives doctors a rare opportunity to connect deeply with families — from the outset of treatment through the course of the disease, sometimes over several years. I value the chance to get to know you and your family and will work intensively with you over time.

Provider background

Specialty: Medical Oncology

Genitourinary cancers

I’m a medical oncologist who specializes in genitourinary oncology — treating patients with prostate, bladder and testicular cancers. Since 2004, I’ve been taking part in innovative cancer research here at SCCA. I work as the director of SCCA’s Prostate Cancer Clinical Research Group and am a member of the Institute for Prostate Cancer Research, a collaboration between Fred Hutchinson Cancer Research Center and UW Medicine. We strive to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics and improve survival and quality of life.

One of my areas of research is focused on developing new imaging compounds for use in PET scans that are easier to use and more likely to detect cancers. My other research interests include cancer treatment-induced bone loss, bone metastases, bone biomarkers, molecular imaging of bone, novel therapeutics and new immunotherapeutic approaches.

Diseases treated

Education, experience and certifications
Medical Degree
University of Washington School of Medicine
Residency
Bringham and Women's Hospital, Internal Medicine
Fellowship
Dana-Farber Cancer Institute, Hematology-Oncology
Board Certification
Medical Oncology, 2003, 2013, American Board of Internal Medicine
Languages
English
Chinese (Mandarin)
Awards
Seattle Magazine's 2018 Top Doctors Award

Dr. Yu has been recognized as a Top Doctor in this peer-nominated award.

U.S. News and World Report “Top Doctor” 2011–present
Castle Connolly America’s Top Doctors 2011–present

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
NCT04579380
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Complete title
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Study ID:
NCT04223856
Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
Complete title
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Study ID:
Complete title
DAROL: Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients

Publications

Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Press

SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

Dr. Yu on the Utility of Enfortumab Vedotin in Metastatic Urothelial Cancer

SCCA’s Evan Yu, MD, was interviewed by OncLive about the utility of enfortumab vedotin-ejfv in patients with urothelial cancer.

Prostate-Specific Membrane Antigen (PSMA) PET for Initial Staging of Prostate Cancer – Now That It’s Regulatory Approved, What’s Next?

SCCA’s Evan Yu, MD wrote about the future of PSMA PET for prostate cancer.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Patient care coordinator
Patient care coordinator
Your patient care coordinator works closely with you and your physician and serves as your scheduler.

Insurance

SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers